Genomic alterations of the PI3K-AKT signaling pathway have been reported in many diverse solid tumors including endometrial, colorectal, cervical, Salivary gland, breast, gastric, ovarian and prostate cancers (Bachman et al., 2004; Samuels et al., 2004; Levine et al., 2005; Sun et al., 2009; Arsenic et al., 2014; Millis et al., 2016). This evidence concerns the gene PIK3CG and prostate carcinoma.